Filing Details
- Accession Number:
- 0001562180-21-007138
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-11-17 19:03:42
- Reporting Period:
- 2021-11-16
- Accepted Time:
- 2021-11-17 19:03:42
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1689813 | Biohaven Pharmaceutical Holding Co Ltd. | BHVN | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1704234 | Declan Doogan | C/O Biohaven Pharmaceuticals, Inc. 215 Church Street New Haven CT 06510 | No | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Shares | Acquisiton | 2021-11-16 | 250,000 | $0.61 | 623,913 | No | 4 | M | Direct | |
| Common Shares | Acquisiton | 2021-11-16 | 175,000 | $5.60 | 798,913 | No | 4 | M | Direct | |
| Common Shares | Acquisiton | 2021-11-16 | 50,000 | $9.29 | 848,913 | No | 4 | M | Direct | |
| Common Shares | Acquisiton | 2021-11-16 | 18,000 | $28.76 | 866,913 | No | 4 | M | Direct | |
| Common Shares | Acquisiton | 2021-11-16 | 18,000 | $61.76 | 884,913 | No | 4 | M | Direct | |
| Common Shares | Acquisiton | 2021-11-16 | 30,000 | $10.82 | 914,913 | No | 4 | M | Direct | |
| Common Shares | Acquisiton | 2021-11-16 | 18,000 | $47.10 | 932,913 | No | 4 | M | Direct | |
| Common Shares | Disposition | 2021-11-16 | 12,437 | $115.90 | 920,476 | No | 4 | S | Direct | |
| Common Shares | Disposition | 2021-11-16 | 18,230 | $116.69 | 902,246 | No | 4 | S | Direct | |
| Common Shares | Disposition | 2021-11-16 | 7,073 | $117.87 | 895,173 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Shares | Stock Option (Right to buy) | Disposition | 2021-11-16 | 250,000 | $0.00 | 250,000 | $0.61 |
| Common Shares | Stock Option (Right to buy) | Disposition | 2021-11-16 | 175,000 | $0.00 | 175,000 | $5.60 |
| Common Shares | Stock Option (Right to buy) | Disposition | 2021-11-16 | 50,000 | $0.00 | 50,000 | $9.29 |
| Common Shares | Stock Option (Right to buy) | Disposition | 2021-11-16 | 18,000 | $0.00 | 18,000 | $28.76 |
| Common Shares | Stock Option (Right to buy) | Disposition | 2021-11-16 | 18,000 | $0.00 | 18,000 | $61.76 |
| Common Shares | Stock Option (Right to buy) | Disposition | 2021-11-16 | 30,000 | $0.00 | 30,000 | $10.82 |
| Common Shares | Stock Option (Right to buy) | Disposition | 2021-11-16 | 18,000 | $0.00 | 18,000 | $47.10 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | 2024-11-25 | No | 4 | M | Direct | |
| 0 | 2025-10-22 | No | 4 | M | Direct | |
| 0 | 2026-12-14 | No | 4 | M | Direct | |
| 0 | 2019-05-01 | 2028-04-30 | No | 4 | M | Direct |
| 0 | 2020-04-30 | 2029-05-20 | No | 4 | M | Direct |
| 0 | 2027-04-05 | No | 4 | M | Direct | |
| 0 | 2021-04-30 | 2030-04-29 | No | 4 | M | Direct |
Reported Non-Derivative Holdings
| Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
|---|---|---|---|
| Common Shares | 626,002 | Indirect | By the Declan Doogan 2014 Trust |
Footnotes
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $115.31 - $116.30, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $116.32 - $117.31, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $117.33 - $118.15, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
- The shares underlying this option vested as to 25% of the shares on November 26, 2014, and the remainder vested in 3 equal installments on the first, second and third anniversaries of the grant date.
- The shares underlying this option vested as to 25% of the shares on October 23, 2015, and the remainder vested in 3 equal installments on the first, second and third anniversaries of the grant date.
- The shares underlying this option vested as to 25% of the shares on December 15, 2016, and the remainder vested in 3 equal installments on the first, second and third anniversaries of the grant date.
- The shares underlying this option vested as to 25% of the shares on April 6, 2017, and the remainder vested in 3 equal installments on the first, second and third anniversaries of the grant date.
Billionaire Hedge Funds
